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INTRODUCTION 
 
Numerous inflammatory and non-inflammatory diseases affect 
the glomerular and lead to alteration in glomerular permeability, 
structure and function. Many glomerular diseases come under the 
genomic title glomerular nephritis (GN) which implies that there is 
immune pathogenesis. Not all glomerular diseases are caused by 
immune pathogenesis and here to be considered in its differential 
diagnosis, particularly important are diabetic nephropathy and 
amyloidosis as well as hereditary nephropathy, most commonly Alport 
syndrome. 
Glomerular nephritis may be primary, restricted in clinical 
manifestations to the kidney or it may be part of multisystem disease, 
most frequently systemic lupus erythematosis and vasculitis. While the 
likelihood of a patient having glomerulo nephritis can be estimated with 
varying degree of confidence from the clinical setting and laboratory test 
it cannot ultimately be diagnosed without histological evidence of renal 
cortical tissue.  
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The underlying cause of most glomerular diseases reminds 
unknown since knowledge of etiology and pathogenesis is rather 
limited. The most reliable classification of glomerular diseases based on 
clinical pathological and laboratory evidence of the disease. 
Different studies by various authors in western countries as well 
as in India have shown varying prevalence of glomerular diseases [1]. 
In this study of pattern of glomerular diseases (primary and 
secondary) an attempt has been made to study the distributions, clinical, 
histopathalogical profile of various glomerular diseases as they occurred 
in this centre (Madras Medical College, Chennai-3) between two study 
periods (i.e., 2000-2006 and 2007-2008). 
This data has been compared with other centre in south India 
(CMC, Vellore and US and European data). 
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REVIEW OF LITERATURE 
 
Most glomerular diseases are immune-mediated, and described by 
the generic term glomerulonephritis (GN). Although the glomerulus is 
the primary site of damage, subsequent injury to the tubulointerstitium 
plays a major role in the overall outcome of glomerular disease.  
Many forms of GN are characterized by the deposition of immune 
reactants, particularly immunoglobulin and complements, in the 
glomerulus which is accompanied by varying degrees of glomerular 
inflammation and injury. However, both cellular and humoral immune 
mechanisms may provoke glomerular injury in the absence of such 
deposits [2].  
The underlying cause of most glomerular diseases remains an 
enigma. Infectious agents, autoimmunity, drugs, inherited disorders, and 
environmental agents have been implicated as causes of certain 
glomerular diseases. Until the precise etiology and pathogenesis of 
glomerular disorders is unraveled, we continue in the tradition of 
Richard Bright—studying the relationship of clinical, pathological, and 
laboratory signs and symptoms of disease, and basing our diagnostic 
categorization on these features rather than on etiology [3]. 
  4
Glomerular diseases may be categorized into those that primarily 
involve the kidney (primary glomerular diseases), and those in which 
kidney involvement is part of a systemic disorder (secondary glomerular 
diseases) [4-5]. 
Overview of mechanisms of glomerular injury 
 
Minimal Change Disease 
MCD, sometimes known as nil lesion, causes 70–90% of 
nephrotic syndrome in childhood but only 10–15% of nephrotic 
syndrome in adults [6, 8]. 
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  MCD usually presents as a primary renal disease but can be 
associated with several other conditions, including Hodgkin's disease, 
allergies, or use of nonsteroidal anti-inflammatory agents; significant 
interstitial nephritis often accompanies cases associated with use of 
nonsteroidal anti-inflammatory drugs. 
MCD on renal biopsy shows no obvious glomerular lesion by 
light microscopy and is negative for deposits by immunofluorescent 
microscopy, or occasionally shows small amounts of IgM in the 
mesangium .  
Electron microscopy, however, consistently demonstrates an 
effacement of the foot process supporting the epithelial podocytes with 
weakening of slit-pore membranes.  
The pathophysiology of this lesion is uncertain. Most agree there 
is a circulating cytokine, perhaps related to a T cell response that alters 
capillary charge and podocyte integrity. The evidence for cytokine-
related immune injury is circumstantial and is suggested by the presence 
of preceding allergies, altered cell-mediated immunity during viral 
infections, and the high frequency of remissions with steroids. 
MCD presents clinically with the abrupt onset of edema and 
nephrotic syndrome accompanied by acellular urinary sediment. 
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 In children, the abnormal urine principally contains albumin with 
minimal amounts of higher molecular weight proteins, and is sometimes 
called selective proteinuria.  
Although up to 30% of children have a spontaneous remission, all 
children today are treated with steroids; only children who are non 
responders are biopsied in this setting [5]. 
Ninety to 95% of children will develop a complete remission after 
8 weeks of steroid therapy, and 80–85% of adults will achieve complete 
remission, but only after a longer course of 20–24 weeks 
Relapses occur in 70–75% of children after the first remission, 
and early relapse predicts multiple subsequent relapses. The frequency 
of relapses decreases after puberty. Relapses are less common in adults 
but are more resistant to subsequent therapy.  
Predinisolone is first-line therapy, and other immunosuppressive 
drugs, such as Cyclophosphamide, Chlorambucil, and Mycophenolate 
Mofetil, Cyclosporine are saved for frequent relapses, steroid-
dependent, or steroid-resistant patients.  
Focal Segmental Glomerulosclerosis 
FSGS refers to a pattern of renal injury characterized by 
segmental glomerular scars that involve some but not all glomeruli; the 
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clinical findings of FSGS largely manifest as proteinuria. The incidence 
of this disease is increasing, and it now represents up to one-third of 
cases of nephrotic syndrome in adults and one-half of cases of nephrotic 
syndrome in African Americans, in whom it is seen more commonly  
[7, 9].  
The pathogenesis of FSGS is probably multifactorial. Possible 
mechanisms include a T cell–mediated circulating permeability factor, 
TGF-–mediated cellular proliferation and matrix synthesis, and 
podocyte abnormalities associated with genetic mutations. 
The pathologic changes of FSGS are most prominent in glomeruli 
located at the corticomedullary junction, so if the renal biopsy specimen 
is from superficial tissue, the lesions can be missed, which sometimes 
leads to a misdiagnosis of MCD. 
In addition to focal and segmental scarring, other variants have 
been described, including cellular lesions with endocapillary 
hypercellularity and heavy proteinuria; collapsing glomerulopathy  
 with segmental or global glomerular collapse and a rapid decline in 
renal function; or the glomerular tip lesion, which seems to have a better 
prognosis [8]. 
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Table 1. Columbia Classification of the Morphologic Variants of 
FSGS 
Variant Positive Criteria Negative Criteria
FSGS, Not 
otherwise 
specified 
• At least one glomerulus with 
segmental increase  Exclude other 
defined variants 
below 
• There may be segmental GBM 
collapse without podocyte 
hyperplasia 
Perihilar 
variant 
• At lease one glomerulus with 
perihilar hyalinosis, with or without 
with hyalinosis Exclude cellular, 
tip, and collapsing 
variants • Perihilar sclerosis and hyalinosis 
involving >50% of segmental 
sclerotic glomerulous 
Cellular 
variant 
• At least one glomerulus with 
segmental endocapillary 
hypercellularity occluding Lumina, 
with or without foam cells and 
karyorrhexis 
Exclude tip and 
collapsing variants
Tip variant 
• At least one segmental lesion 
involving the tip domain (outer 
25% of the tuft next to the origin of 
the proximal tubule) Exclude collapsing 
variant 
exclude if any 
glomeruli show 
perihilar sclerosis 
• The tubular pole must be identified 
in the defining lesion 
• The lesion must have either an 
adhesion or confluence of 
podocytes with parietal or tubular 
cells at the tubular lumen or neck 
Collapsing 
variant 
• The tip lesion may be sclerosing or 
cellular  
No exclusions • At least one glomerulus with 
segmental or global collapse and 
podocyte hypertrophy  
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Secondary FSGS 
With IV drug abuse  
With HIV disease 
With other drugs (e.g., pamidronate, interferon) 
  With identified genetic abnormalities (e.g., in podocin, alpha- 
actinin-4, TRPC6) 
 With glomerulomegaly 
Morbid obesity 
Sickle cell disease 
Cyanotic congenital heart disease 
Hypoxic pulmonary disease 
With reduced nephron numbers 
  Unilateral renal agenesis 
 Oligomeganephronemia 
 Reflux-interstitial nephritis 
 Post-focal cortical necrosis 
 Post nephrectomy 
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FSGS can present with any level of proteinuria, hematuria, 
hypertension, or renal insufficiency.  
FSGS rarely remits spontaneously, but treatment-induced 
remission of proteinuria significantly improves prognosis. 
Treatment of patients with primary FSGS should include 
inhibitors of the renin-angiotensin system. Based on retrospective 
studies, patients with nephrotic range proteinuria can be treated with 
steroids but respond far less often than patients with MCD. Proteinuria 
remits in only 20–45% of patients receiving a course of steroids over  
6–9 months. Use of cyclosporine in steroid-responsive patients helps 
ensure remissions, while other cytotoxic agents confer little added 
benefit over steroid therapy.  
Primary FSGS recurs in 25–40% of patients given allografts at 
end-stage disease, leading to graft loss in half of those cases. The 
treatment of secondary FSGS typically involves treating the underlying 
cause and controlling proteinuria. There is no role for steroids or other 
immunosuppressive agents in secondary FSGS. 
Membranous Glomerulonephritis 
MGN, or membranous nephropathy as it is sometimes called, 
accounts for approximately 30% of cases of nephrotic syndrome in 
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adults, with a peak incidence between the ages of 30–50 years and a 
male to female ratio of 2:1. It is rare in childhood and by far the most 
common cause of nephrotic syndrome in the elderly [9]. 
In 25–30% of cases, MGN is secondary to malignancy (solid 
tumors of the breast, lung, colon), infection (Hepatitis B, Malaria, 
Schistosomiasis), or Rheumatologic disorders like lupus or rarely 
rheumatoid arthritis. 
It is rare in childhood and by far the most common cause of 
nephrotic syndrome in the elderly. 
Primary/idiopathic membranous glomerulonephritis 
Secondary membranous glomerulonephritis 
Infection: Hepatitis B and C, Syphilis, Malaria, Schistosomiasis, 
Leprosy, Filariasis. 
Cancer: Breast, colon, lung, stomach, kidney, esophagus, 
neuroblastoma. 
Drugs: gold, mercury, penicillamine, nonsteroidal anti-
inflammatory agents, probenecid. 
Autoimmune diseases: Systemic lupus erythematosus, 
Rheumatoid arthritis, Hashimoto's thyroiditis. 
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Uniform thickening of the basement membrane along the 
peripheral capillary loops is seen by light microscopy on renal biopsy; 
this thickening needs to be distinguished from that seen in diabetes and 
amyloidosis.  
Immunofluorescence demonstrates diffuse granular deposits of 
IgG and C3, and electron microscopy typically reveals electron-dense 
subepithelial deposits. The presence of subendothelial deposits or the 
presence of tubuloreticular inclusions strongly points to a diagnosis of 
membranous lupus nephritis, which may precede the extrarenal 
manifestations of lupus.  
Table 2. Pathological Staging of Membranous Nephropathy 
Stage Electron Microscopy 
I Sub epithelial electron–dense deposits  
II Sub-epithelial electron – dense deposits with intervening 
basement membrane (“spikes”) 
III Incorporation of sub-epithelial electron – dense deposits 
into the basement membrane 
IV 1. Reabsorption of deposits with loss of electron – dense 
deposits and development of lucent area in the 
basement membrane. 
2. Remodeling of basement membrane and loss of 
electron – dense deposits.  
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  Heyman’s nephritis, an animal model of MGN, suggests that 
glomerular lesions result from in situ formation of immune complexes 
with megalin receptor–associated protein as the putative antigen. This 
antigen is not found in human podocytes, but human antibodies have 
been described against neutral endopeptidase expressed by podocytes, 
hepatitis antigens B/C, tumor antigens, and thyroglobulin. 
Eighty percent of patients with MGN present with nephrotic 
syndrome and nonselective proteinuria. Microscopic hematuria is seen 
in up to 50% of patients. Spontaneous remissions occur in 20–33% of 
patients and often occur late in the course after years of nephrotic 
syndrome. One-third of patients continue to have relapsing nephrotic 
syndrome but maintain normal renal function, and approximately 
another third of patients develop renal failure or die from the 
complications of nephrotic syndrome [10, 11].  
Male gender, older age, hypertension, and the persistence of 
proteinuria are associated with worse prognosis. Although thrombotic 
complications are a feature of all nephrotic syndrome. 
  MGN has the highest reported incidences of renal vein 
thrombosis, pulmonary embolism, and deep vein thrombosis. 
Prophylactic anticoagulation is controversial but has been recommended 
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for patients with severe or prolonged proteinuria in the absence of risk 
factors for bleeding. 
In addition to the treatment of edema, dyslipidemia, and 
hypertension, inhibition of the renin-angiotensin system is 
recommended. Therapy with immunosuppressive drugs is also 
recommended for patients with primary MGN and persistent proteinuria 
(>4.0 g/24 h) and in renal failure.  
IgA Nephropathy 
Berger first described the glomerulonephritis termed IgA 
nephropathy. It is classically characterized by episodic hematuria 
associated with the deposition of IgA in the mesangium. IgA 
nephropathy is one of the most common forms of glomerulonephritis 
worldwide. There is a male preponderance, a peak incidence in the 
second and third decades of life, and rare familial clustering [12]. 
  Henoch-Schönlein purpura is distinguished clinically from IgA 
nephropathy by prominent systemic symptoms, a younger age  
(<20 years old), preceding infection, and abdominal complaints. 
Deposits of IgA are also found in the glomerular mesangium in a variety 
of systemic diseases, including chronic liver disease, Crohn's disease, 
gastrointestinal adenocarcinoma, chronic obstructive bronchiectasis, 
idiopathic interstitial pneumonia, dermatitis herpetiformis, mycosis 
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fungiodes, leprosy, ankylosing spondylitis, relapsing polychondritis, and 
Sjögren's syndrome. IgA deposition in these entities is not usually 
associated with clinically significant glomerular inflammation or renal 
dysfunction and thus is not called IgA nephropathy. 
IgA nephropathy is an immune complex-mediated 
glomerulonephritis defined by the presence of diffuse mesangial IgA 
deposits often associated with mesangial hypercellularity. IgM, IgG, C3, 
or immunoglobulin light chains may be co-distributed with IgA. IgA 
deposited in the mesangium is typically polymeric and of the IgA1 
subclass, the pathogenic significance of which is not clear. 
Abnormalities have been described in IgA production by plasma 
cells, particularly secretory IgA; in IgA O-glycosylation; in IgA 
clearance, predominately by the liver; in mesangial IgA clearance and 
receptors for IgA; and in growth factor and cytokine-mediated events. 
Despite the presence of elevated serum IgA levels in 20–50% of 
patients, IgA deposition in skin biopsies in 15–55% of patients, or 
elevated levels of secretory IgA and IgA-fibronectin complexes 
Although the immunofluorescent pattern of IgA on renal biopsy 
defines IgA nephropathy in the proper clinical context, a variety of 
histologic lesions may be seen on light microscopy, including DPGN; 
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segmental sclerosis; and, rarely, segmental necrosis with cellular 
crescent formation, which typically presents as RPGN. 
The two most common presentations of IgA nephropathy are 
recurrent episodes of macroscopic hematuria during or immediately 
following an upper respiratory infection in children (Henoch-Schönlein 
purpura) or asymptomatic microscopic hematuria most often seen in 
adults. Between episodes, the urinalysis is normal. When the hematuria 
persists, one finds increasing amounts of proteinuria; nephrotic 
syndrome, however, is uncommon.. Rarely, patients can present with 
acute renal failure and a rapidly progressive clinical picture. 
IgA nephropathy is a benign disease for the majority of patients, 
with progression to renal failure seen in only 25–30% over 20–25 years; 
in fact, 5–30% of patients go into complete remission. Risk factors for 
the loss of renal function include the presence of hypertension or 
proteinuria, the absence of episodes of macroscopic hematuria, male 
age, older age of onset, and more severe changes on renal biopsy [13]. 
There is no agreement on optimal treatment. Both large studies 
that include patients with multiple glomerular diseases or small studies 
of patients with IgA nephropathy support the use of angiotensin-
converting enzyme (ACE) inhibitors in patients with proteinuria or 
declining renal function. Tonsillectomy, steroid therapy, and fish oil 
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have all been suggested in small studies to benefit select patients with 
IgA nephropathy. When presenting as RPGN, patients typically receive 
steroids, cytotoxic agents, and plasmapheresis. 
Post streptococcal Glomerulonephritis 
Post streptococcal glomerulonephritis is prototypical for acute 
endocapillary proliferative glomerulonephritis. Acute post streptococcal 
glomerulonephritis typically affects children between the ages of 2 and 
14 years, but 10% of cases are patients older than 40. It is more common 
in males, and the familial or cohabitant incidence is as high as 40%. 
  Skin and throat infections with particular M types of streptococci 
(nephritogenic strains) antedate glomerular disease; M types 47, 49, 55, 
2, 60, and 57 are seen following impetigo and M types 1, 2, 4, 3, 25, 49, 
and 12 with pharyngitis. Post streptococcal glomerulonephritis due to 
impetigo develops 2–6 weeks after skin infection and 1–3 weeks after 
streptococcal pharyngitis.  
The renal biopsy in post streptococcal glomerulonephritis 
demonstrates hypercellularity of mesangial and endothelial cells, 
glomerular infiltrates of polymorphonuclear leukocytes, granular 
subendothelial immune deposits of IgG, IgM, C3, and subepithelial 
deposits (which appear as "humps").  
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Post streptococcal glomerulonephritis is an immune-mediated 
disease involving putative streptococcal antigens, circulating immune 
complexes, and activation of complement in association with cell-
mediated injury. Many candidate antigens have been proposed over the 
years; three such candidates from nephritogenic streptococci are 
zymogen, a precursor of exotoxin B; glyceraldehyde phosphate 
dehydrogenase, also known as prescribing antigen (PA-Ag); and 
streptokinase. All have a biochemical affinity for GBMs, and in this 
location they may act as a target for antibodies. 
The classic presentation is an acute nephritic picture with 
hematuria, pyuria, red blood cell casts, edema, hypertension, and 
oliguric renal failure, which may be severe enough to appear as RPGN. 
Systemic symptoms of headache, malaise, anorexia, and flank pain (due 
to swelling of the renal capsule) are reported in as many as 50% of 
cases. 
Five percent of children and 20% of adults have proteinuria in the 
nephrotic range. In the first week of symptoms, 90% of patients will 
have a depressed CH50 and decreased levels of C3 with normal levels of 
C4. 
Positive cultures for streptococcal infection are inconsistently 
present (10–70%), but increased titers of ASO (30%), anti-DNAase 
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(70%) or antihyaluronidase antibodies (40%) can help confirm the 
diagnosis.  
Treatment is supportive, with control of hypertension, edema, and 
dialysis as needed. Antibiotic treatment for streptococcal infection 
should be given to all patients and their cohabitants. There is no role for 
immunosuppressive therapy, even in the setting of crescents. Recurrent 
post streptococcal glomerulonephritis is rare despite repeated 
streptococcal infections. 
Overall, the prognosis is good, with permanent renal failure being 
very uncommon (1–3%), and even less so in children. Complete 
resolution of the hematuria and proteinuria in children occurs within 3–6 
weeks of the onset of nephritis.  
Membranoproliferative Glomerulonephritis 
MPGN is sometimes called mesangiocapillary glomerulonephritis 
or lobar glomerulonephritis. It is an immune-mediated 
glomerulonephritis characterized by thickening of the GBM with 
mesangioproliferative changes; 70% of patients have 
hypocomplementemia. MPGN is rare in African Americans, and 
idiopathic disease usually presents in childhood or young adulthood. 
MPGN is subdivided pathologically into Type I, Type II, and Type III 
disease. Type I MPGN is commonly associated with persistent  
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hepatitis C infections, autoimmune diseases like lupus or 
cryoglobulinemia, or neoplastic diseases. Types II and III MPGN are 
usually idiopathic, except in the presence of C3 nephritic factor and/or in 
partial lipodystrophy producing Type II disease or complement receptor 
deficiency in Type III disease. 
Type I Disease (Most Common)  
• Idiopathic 
• Subacute bacterial endocarditis 
• Systemic lupus erythematosus 
• Hepatitis C ± cryoglobulinemia 
• Mixed cryoglobulinemia 
• Hepatitis B 
• Cancer: Lung, breast, and ovary (germinal) 
Type II Disease (Dense Deposit Disease)  
• Idiopathic 
• C3 nephritic factor-associated 
• Partial lipodystrophy 
Type III Disease  
• Idiopathic 
• Complement receptor deficiency 
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Type I MPGN, the most proliferative of the three types, shows 
mesangial proliferation with lobular segmentation on renal biopsy and 
mesangial interposition between the capillary basement membrane and 
endothelial cells, producing a double contour sometimes called tram-
tracking. Subendothelial deposits with low serum levels of C3 are 
typical, although 50% of patients have normal levels of C3 and 
occasional intra-mesangial deposits. 
 Low serum C3 and a dense thickening of the GBM containing 
ribbons of dense deposits and C3 characterize Type II MPGN, 
sometimes called dense deposit disease. Classically, the glomerular tuft 
has a lobular appearance; intramesangial deposits are rarely present and 
subendothelial deposits are generally absent. 
Proliferation in Type III MPGN is less common than the other 
two types and is often focal; mesangial interposition is rare, and 
subepithelial deposits can occur along widened segments of the GBM 
that appear laminated and disrupted.  
Type I MPGN is secondary to glomerular deposition of 
circulating immune complexes or their in situ formation. Types II and 
III MPGN may be related to "nephritic factors," which are 
autoantibodies that stabilize C3 convertase and allow it to activate  
serum C3.  
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Patients with MPGN present with proteinuria, hematuria, and 
pyuria (30%), systemic symptoms of fatigue and malaise that are most 
common in children with Type I disease, or an acute nephritic picture 
with RPGN and a speedy deterioration in renal function in up to 25% of 
patients. Low serum C3 levels are common. Fifty percent of patients 
with MPGN develop end-stage disease 10 years after diagnosis, and 
90% have renal insufficiency after 20 years. Nephrotic syndrome, 
hypertension, and renal insufficiency all predict poor outcome. 
  Although all primary renal diseases can recur over time in 
transplanted renal allografts, patients with MPGN are well known to be 
at risk for this adverse event. 
Diabetic Nephropathy 
Diabetic nephropathy is the single most common cause of chronic 
renal failure in the United States, accounting for 45% of patients 
receiving renal replacement therapy, and is a rapidly growing problem 
worldwide. 
 The dramatic increase in the number of patients with diabetic 
nephropathy reflects the epidemic increase in obesity, metabolic 
syndrome, and Type 2 diabetes mellitus. Approximately 40% of patients 
with Types 1 or Type 2 diabetes develop nephropathy, but due to the 
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higher prevalence of Type 2 diabetes (90%) compared to Type 1 (10%), 
the majority of patients with diabetic nephropathy have Type 2 disease. 
  Risk factors for the development of diabetic nephropathy include 
hyperglycemia, hypertension, dyslipidemia, smoking, a family history of 
diabetic nephropathy, and gene polymorphisms affecting the activity of 
the renin-angiotensin-aldosterone axis. 
Within 1–2 years after the onset of clinical diabetes, morphologic 
changes appear in the kidney. Thickening of the GBM is a sensitive 
indicator for the presence of diabetes but correlates poorly with the 
presence or absence of clinically significant nephropathy. The 
composition of the GBM is altered notably with a loss of heparan sulfate 
moieties that form the negatively charged filtration barrier. This change 
results in increased filtration of serum proteins into the urine, 
predominately negatively charged albumin. The expansion of the 
mesangium due to the accumulation of extracellular matrix correlates 
with the clinical manifestations of diabetic nephropathy. This expansion 
in mesangial matrix can be associated with the development of 
mesangial sclerosis. Some patients also develop eosinophilic, PAS+ 
nodules called nodular glomerulosclerosis or Kimmelstiel-Wilson 
nodules. Immunofluorescence microscopy often reveals the nonspecific 
deposition of IgG (at times in a linear pattern) or complement staining 
without immune deposits on electron microscopy. Prominent vascular 
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changes are frequently seen with hyaline and hypertensive 
arteriosclerosis. This is associated with varying degrees of chronic 
glomerulosclerosis and tubulointerstitial changes. Renal biopsies from 
patients with Types 1 and Type 2 diabetes are largely indistinguishable.  
Since the onset of Type 1 diabetes is readily identifiable and the 
onset of Type 2 diabetes is not, a patient newly diagnosed with Type 2 
diabetes may have renal disease for many years before nephropathy is 
discovered and presents as advanced diabetic nephropathy. At the onset 
of diabetes, renal hypertrophy and glomerular hyperfiltration are 
present. The degree of glomerular hyperfiltration correlates with the 
subsequent risk of clinically significant nephropathy. 
In the approximately 40% of patients with diabetes who develop 
diabetic nephropathy, the earliest manifestation is an increase in 
albuminuria detected by sensitive radioimmunoassay. Albuminuria in 
the range of 30–300 mg/24 h is called microalbuminuria. In patients 
with Types 1 or Type 2 diabetes, microalbuminuria appears 5–10 years 
after the onset of diabetes. It is currently recommended to test patients 
with Type1 disease for microalbuminuria 5 years after diagnosis of 
diabetes and yearly thereafter, and, because the time of onset of Type 2 
diabetes is often unknown, to test Type 2 patients at the time of 
diagnosis of diabetes and yearly thereafter [14].  
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Microalbuminuria is a potent risk factor for cardiovascular events 
and death in patients with Type2 diabetes. Many patients with Type2 
diabetes and microalbuminuria succumb to cardiovascular events before 
they progress to proteinuria or renal failure. Proteinuria in frank diabetic 
nephropathy can be variable, ranging from 500 mg to 25 g/24 h, and is 
often associated with nephrotic syndrome.  
More than 90% of patients with Type1 diabetes and nephropathy 
have diabetic retinopathy, so the absence of retinopathy in Type 1 
patients with proteinuria should prompt consideration of a diagnosis 
other than diabetic nephropathy; only 60% of patients with Type 2 
diabetes with nephropathy have diabetic retinopathy. There is a highly 
significant correlation between the presence of retinopathy and the 
presence of Kimmelstiel-Wilson nodules [15]. 
  Also, characteristically, patients with advanced diabetic 
nephropathy have normal to enlarged kidneys, in contrast to other 
glomerular diseases where kidney size is usually decreased. Using the 
above epidemiologic and clinical data, and in the absence of other 
clinical or serologic data suggesting another disease, diabetic 
nephropathy is usually diagnosed without a renal biopsy [16]. 
 After the onset of proteinuria >500 mg/24 h, renal function 
inexorably declines, with 50% of patients reaching renal failure in  
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5–10 years; thus, from the earliest stages of microalbuminuria, it usually 
takes 10–20 years to reach end-stage renal disease.  
Hypertension may predict which patients develop diabetic 
nephropathy, as the presence of hypertension accelerates the rate of 
decline in renal function.  
Good evidence supports the benefits of blood sugar and blood 
pressure control as well as inhibition of the renin-angiotensin system in 
retarding the progression of diabetic nephropathy. In patients with 
Type1 diabetes, intensive control of blood sugar clearly prevents the 
development or progression of diabetic nephropathy. The evidence in 
patients with Type 2 disease, although less compelling, also supports 
intensive control of blood sugar. Controlling systemic blood pressure to 
levels of 130/80 mmHg or less decreases renal and cardiovascular 
adverse events in this high-risk population. The vast majority of patients 
with diabetic nephropathy require three or more antihypertensive drugs 
to achieve this goal. Drugs that inhibit the renin-angiotensin system, 
independent of their effects on systemic blood pressure, have been 
repeatedly shown to slow the progression of diabetic nephropathy at 
early (microalbuminuria) and late (proteinuria with reduced glomerular 
filtration) stages, independent of any effect they may have on systemic 
blood pressure. 
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Since angiotensin II increases efferent arteriolar resistance and, 
hence, glomerular capillary pressure, one key mechanism for the 
efficacy of ACE inhibitors or angiotensin receptor blockers (ARBs) is 
reducing glomerular hypertension. Patients with Type1 diabetes for 5 
years who develop albuminuria or declining renal function should be 
treated with ACE inhibitors. Patients with Type2 diabetes and 
microalbuminuria or proteinuria may be treated with ACE inhibitors or 
ARBs [17]. 
Renal Amyloidosis 
Most renal amyloidosis is either the result of primary fibrillar 
deposits of immunoglobulin light chains [amyloid L (AL)], or secondary 
to fibrillar deposits of serum amyloid A (AA) protein fragments. Even 
though both occur for different reasons, their clinicopathophysiology is 
quite similar and will be discussed together. Amyloid infiltrates the 
liver, heart, peripheral nerves, carpal tunnel, upper pharynx, and kidney, 
producing restrictive cardiomyopathy, hepatomegaly, macroglossia, and 
heavy proteinuria sometimes associated with renal vein thrombosis.  
In systemic AL amyloidosis, also called primary amyloidosis, 
light chains produced in excess by clonal plasma cell dyscrasias are 
made into fragments by macrophages so they can self-aggregate at acid 
pH. A disproportionate number of these light chains (75%) are of the 
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lambda class. About 10% of these patients have overt myeloma with 
lytic bone lesions and infiltration of the bone marrow with >30% plasma 
cells; nephrotic syndrome is common, and about 20% of patients 
progress to dialysis. 
AA amyloidosis is sometimes called secondary amyloidosis and 
also affects the kidney with nephrotic syndrome. It is due to deposition 
of -pleated sheets of serum amyloid A protein, an acute phase reactant 
whose physiologic function is unknown. Forty percent of patients with 
AA amyloid have rheumatoid arthritis, and another 10% have 
ankylosing spondylitis or psoriatic arthritis; the rest derive from other 
lesser causes.  
Fragments of serum amyloid A protein increase and self-
aggregate by attaching to receptors for advanced glycation end products 
in the extracellular environment; nephrotic syndrome is common, and 
about 40–60% of patients progress to dialysis.  
AA and AL amyloid fibrils are detectable with Congo red or in 
more detail with electron microscopy. Biopsy of involved liver or 
kidney is diagnostic 90% of the time when the pretest probability is 
high; abdominal fat pad aspirates are positive about 70% of the time, but 
apparently less so when looking for AA amyloid. Amyloid deposits are 
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distributed along blood vessels and in the mesangial regions of the 
kidney.  
The treatment for primary amyloidosis is not particularly 
effective; Melphalan and autologous hematopoietic stem cell 
transplantation can delay the course of disease in about 30% of patients. 
Secondary amyloidosis is also relentless unless the primary disease can 
be controlled. Some new drugs in development that disrupt the 
formation of fibrils may be available in the future [18]. 
Lupus Nephritis 
Lupus nephritis is a common and serious complication of 
systemic lupus erythematosus (SLE) and most severe in African-
American female adolescents. Thirty to fifty percent of patients will 
have clinical manifestations of renal disease at the time of diagnosis, and 
60% of adults and 80% of children develop renal abnormalities at some 
point in the course of their disease. Lupus nephritis results from the 
deposition of circulating immune complexes, which activate the 
complement cascade leading to complement-mediated damage, 
leukocyte infiltration, activation of procoagulant factors, and release of 
various cytokines. In situ immune complex formation following 
glomerular binding of nuclear antigens may also play a role in renal 
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injury. The presence of antiphospholipid antibodies may trigger a 
thrombotic microangiopathy in a minority of patients. 
Table 3. Pathological Indices of Activity and Tonicity in Lupus 
Nephritis  
Chronicity Index Activity Index 
Glomerular sclerosis  Cellular proliferation  
Fibrous crescents  Fibrinoid necrosis, Karyorrhexis  
Tubular Atrophy  Cellular Atrophy  
Interstitial Fibrosis  1. Hyaline thrombi , wire loop lesions  
2. Leukocyte infiltration in 
glomerulus  
3. Mononuclear –cell infiltration in 
interstitium 
 
Importance of biopsy in Lupus 
Border Suggested > 6 RBC / HPF and urine protein  
> 200mg / 24hrs. Abnormal serum creatinine [18]. Mahajan et al. 
described 12 patients with diffused proliferative lupus nephritis but 
without clinical or laboratory evidence of renal involvement so biopsy 
recommended in patients with SLE even in the absence of overt clinical 
renal involvement [19]. 
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 Histological scoring system for lupus nephritis is an effort to 
accurately predict the renal outcome and to help to determine which 
patients are likely to benefit from aggressive therapy. 
The clinical manifestations, course of disease, and treatment of 
lupus nephritis are closely linked to the renal pathology. The most 
common clinical sign of renal disease is proteinuria, but hematuria, 
hypertension, varying degrees of renal failure, and active urine sediment 
with red blood cell casts can all be present.  
The extrarenal manifestations of lupus are important in 
establishing a firm diagnosis of systemic lupus because, while serologic 
abnormalities are common in lupus nephritis, they are not diagnostic. 
Anti-dsDNA antibodies that fix complement correlate best with the 
presence of renal disease. Hypocomplementemia is common in patients 
with acute lupus nephritis (70–90%) and declining complement levels 
may herald a flare. Renal biopsy, however, is the only reliable method 
of identifying the morphologic variants of lupus nephritis.  
The World Health Organization (WHO) workshop in 1974 first 
outlined several distinct patterns of lupus-related glomerular injury; 
these were modified in 1982. In 2004 the International Society of 
Nephrology in conjunction with the Renal Pathology Society again 
updated the classification. This latest version of lesions seen on biopsy 
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best defines clinicopathologic correlations, provides valuable prognostic 
information, and forms the basis for modern treatment 
recommendations. 
Class I nephritis describes normal glomerular histology by any 
technique or normal light microscopy with minimal mesangial deposits 
on immunofluorescent or electron microscopy. Class II designates 
mesangial immune complexes with mesangial proliferation. Both Class I 
and II lesions are typically associated with minimal renal manifestation 
and normal renal function; nephrotic syndrome is rare. Patients with 
lesions limited to the renal mesangium have an excellent prognosis and 
generally do not need therapy for their lupus nephritis.  
Table 4. Revised in 2004 by the International Society of Nephrology-
Renal Pathology Society Study Group. 
Class I  Minimal 
mesangial 
Normal histology with mesangial deposits 
Class II  Mesangial 
proliferation 
Mesangial hypercellularity with expansion of the 
mesangial matrix 
Class III  Focal 
nephritis 
Focal endocapillary ± extracapillary proliferation with 
focal subendothelial immune deposits and mild 
mesangial expansion 
Class IV  Diffuse 
nephritis 
Diffuse endocapillary ± extracapillary proliferation 
with diffuse subendothelial immune deposits and 
mesangial alterations. 
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Class V  Membranous 
nephritis 
Thickened basement membranes with diffuse 
subepithelial immune deposits; may occur with Class 
III or IV lesions and is sometimes called mixed 
membranous and proliferative nephritis 
Class VI  Sclerotic 
nephritis 
Global sclerosis of nearly all glomerular capillaries 
 
 
The subject of lupus nephritis is presented under acute nephritic 
syndromes because of the aggressive and important proliferative lesions 
seen in Class III–V renal disease.  
Class III describes focal lesions with proliferation or scarring, 
often involving only a segment of the glomerulus Class III lesions have 
the most varied course. Hypertension, an active urinary sediment, and 
proteinuria are common with nephrotic-range proteinuria in 25–33% of 
patients. Elevated serum creatinine is present in 25% of patients. 
Patients with mild proliferation involving a small percentage of 
glomeruli respond well to therapy with steroids alone, and fewer than 
5% progress to renal failure over 5 years. Patients with more severe 
proliferation involving a greater percentage of glomeruli have a far 
worse prognosis and may have lower remission rates. Treatment of 
those patients is the same as that for Class IV lesions, as some 
nephrologists believe that Class III lesions are simply an early 
presentation of Class IV disease. 
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  Class IV describes global, diffuse proliferative lesions involving 
the vast majority of glomeruli. Patients with Class IV lesions commonly 
have high anti-DNA antibody titers, low serum complement, hematuria, 
red blood cell casts, proteinuria, hypertension, and decreased renal 
function; 50% of patients have nephrotic-range proteinuria. Patients 
with crescents on biopsy may have a rapidly progressive decline in renal 
function. Without treatment, this aggressive lesion has the worst renal 
prognosis. However, if a remission is achieved with treatment, renal 
outcomes are excellent. Treatment must combine high-dose steroids 
with either Cyclophosphamide or Mycophenolate Mofetil. Current 
evidence suggests that inducing a remission with administration of 
steroids and either Cyclophosphamide or Mycophenolate Mofetil for  
2–6 months, followed by maintenance therapy with lower doses of 
steroids and Mycophenolate Mofetil, may best balance the likelihood of 
successful remission with the side effects of therapy. 
 The Class V lesion describes subepithelial immune deposits 
producing a membranous pattern; a subcategory of Class V lesions is 
associated with proliferative lesions and is sometimes called mixed 
membranous and proliferative disease. Sixty percent of patients present 
with nephrotic syndrome or lesser amounts of proteinuria. Patients with 
lupus nephritis Class V, like patients with idiopathic membranous 
nephropathy, are predisposed to renal-vein thrombosis and other 
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thrombolic complications. A minority of patients with Class V will 
present with hypertension and renal dysfunction.. Patients with severe 
nephrotic syndrome, elevated serum creatinine, and a progressive course 
will probably benefit from therapy with steroids in combination with 
other immunosuppressive agents. Therapy with inhibitors of the renin-
angiotensin system also may attenuate the proteinuria.  
Patients with any of the above lesions also can transform to 
another lesion; hence patients often require reevaluation, including 
repeat renal biopsy. Lupus patients with Class VI lesions have greater 
than 90% sclerotic glomeruli and end-stage renal disease with interstitial 
fibrosis. As a group, approximately 20% of patients with lupus nephritis 
will reach end-stage disease, requiring dialysis or transplantation. 
Systemic lupus tends to become quiescent once there is renal failure, 
perhaps due to the immunosuppressant effects of uremia. Renal 
transplantation in renal failure from lupus, usually performed after 
approximately 6 months of inactive disease, results in allograft survival 
rates comparable to patients transplanted for other reasons. 
Antiglomerular Basement Membrane Disease 
Patients who develop autoantibodies directed against glomerular 
basement antigens frequently develop a glomerulonephritis termed 
antiglomerular basement membrane (anti-GBM) disease. When they 
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present with lung hemorrhage and glomerulonephritis, they have a 
pulmonary-renal syndrome called Good pasture's syndrome.  
The target epitopes for this autoimmune disease lie in the 
quaternary structure of 3 NC1 domain of collagen IV. MHC-restricted T 
cells initiate the autoantibody response because humans are not tolerant 
to the epitopes created by this quaternary structure. The epitopes are 
normally sequestered in the collagen IV hexamer and can be exposed by 
infection, smoking, oxidants, or solvents. Good pasture's syndrome 
appears in two age groups: in young men in their late 20s and in men 
and women in their 60–70s. 
Disease in the younger age group is usually explosive, with 
hemoptysis, a sudden fall in hemoglobin, fever, dyspnoea, and 
hematuria. Hemoptysis is largely confined to smokers, and those who 
present with lung hemorrhage as a group do better than older 
populations who have prolonged, asymptomatic renal injury; 
presentation with oliguria is often associated with a particularly bad 
outcome [20]. 
The performance of an urgent kidney biopsy is important in 
suspected cases of Good pasture's syndrome to confirm the diagnosis 
and assess prognosis. Renal biopsies typically show focal or segmental 
necrosis that later, with aggressive destruction of the capillaries by 
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cellular proliferation, leads to crescent formation in Bowman's space.  
As these lesions progress, there is concomitant interstitial nephritis with 
fibrosis and tubular atrophy. The presence of anti-GBM antibodies and 
complement is recognized on biopsy by linear immunofluorescent 
staining for IgG . 
  Between 10–15% of sera from patients with Good pasture's 
syndrome also contain ANCA antibodies against myeloperoxidase. This 
subset of patients has a vasculitis-associated variant, which has a 
surprisingly good prognosis with treatment. 
  Prognosis at presentation is worse if there are >50% crescents on 
renal biopsy with advanced fibrosis, if serum creatinine is >5–6 mg/dL, 
if oliguria is present, or if there is a need for acute dialysis. Patients with 
advanced renal failure who present with hemoptysis should still be 
treated for their lung hemorrhage, as it responds to plasmapheresis and 
can be lifesaving. Treated patients with less severe disease typically 
respond to 8–10 treatments of plasmapheresis accompanied by oral 
prednisone and Cyclophosphamide in the first 2 weeks.  
  Kidney transplantation is possible, but because there is risk of 
recurrence, patients should wait for 6 months and until serum antibodies 
are undetectable. 
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ANCA Small Vessel Vasculitis 
A group of patients with small-vessel vasculitis (arterioles, 
capillaries, and venules; rarely small arteries) and glomerulonephritis 
have serum ANCA; the antibodies are of two types, anti-proteinase 3 
(PR3) or anti-myeloperoxidase (MPO). ANCA are produced with the 
help of T cells and activate leukocytes and monocytes, which together 
damage the walls of small vessels. Endothelial injury also attracts more 
leukocytes and extends the inflammation. Wegener's granulomatosis, 
microscopic polyangiitis, and Churg-Strauss syndrome belong to this 
group because they are ANCA-positive and have a pauci-immune 
glomerulonephritis with few immune complexes in small vessels and 
glomerular capillaries. Patients with any of these three diseases can have 
any combination of the above serum antibodies, but anti-PR3 antibodies 
are more common in Wegener's and anti-MPO antibodies are more 
common in microscopic polyangiitis or Churg-Strauss. While each of 
these diseases have some unique clinical features, most features do not 
predict relapse or progression, and as a group they are generally treated 
in the same way. Only the presence of upper-airway involvement, 
persistent pulmonary injury, and anti-PR3 antibodies suggests that the 
course of disease will be more difficult. Induction therapy usually 
includes some combination of Plasmapheresis, Methylprednisolone, and 
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Cyclophosphamide. The benefit of Plasmapheresis in this setting is 
uncertain.  
The steroids are tapered soon after acute inflammation subsides, 
and patients are maintained on Cyclophosphamide or Azathioprine for 
up to a year to minimize the risk of relapse. 
Wegener's Granulomatosis 
Patients with this disease classically present with fever, purulent 
rhinorrhea, nasal ulcers, sinus pain, polyarthralgias/arthritis, cough, 
hemoptysis, shortness of breath, microscopic hematuria, and 0.5–1 g / 
24 h of proteinuria; occasionally there may be cutaneous purpura and 
mononeuritis multiplex. Presentation without renal involvement is 
termed limited Wegener's granulomatosis, although some of these 
patients will show signs of renal injury later. Chest x-ray often reveals 
nodules and persistent infiltrates, sometimes with cavities. Biopsy of 
involved tissue will show a small-vessel vasculitis and adjacent 
noncaseating granulomas. Renal biopsies during active disease 
demonstrate segmental necrotizing glomerulonephritis without immune 
deposits. The cause of Wegner's granulomatosis is unknown. 
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Microscopic Polyangiitis  
Clinically, these patients look somewhat similar to those with 
Wegener's granulomatosis, except they rarely have significant lung 
disease or destructive sinusitis. The distinction is made on biopsy where 
the vasculitis in microscopic polyangiitis is without granulomas. Some 
patients will also have injury limited to the capillaries and venules. 
Churg-Strauss Syndrome  
When small-vessel vasculitis is associated with peripheral 
eosinophilia, cutaneous purpura, mononeuritis, asthma, and allergic 
rhinitis, a diagnosis of Churg-Strauss syndrome is considered. 
Hypergammaglobulinemia, elevated levels of serum IgE, or the 
presence of rheumatoid factor sometimes accompanies the allergic state. 
Lung inflammation, including fleeting cough and pulmonary infiltrates, 
often precedes the systemic manifestations of disease by years; lung 
manifestations are rarely absent. A third of patients may have exudative 
pleural effusions associated with eosinophils. Small-vessel vasculitis 
and focal segmental necrotizing glomerulonephritis can be seen on renal 
biopsy, usually absent eosinophils or granuloma. The cause of Churg-
Strauss syndrome is autoimmune, but the inciting factors are unknown. 
Interestingly, some asthma patients treated with leukotriene receptor 
antagonists will develop this vasculitis. 
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OBJECTIVES OF THE STUDY 
 
1. To study and analyse the clinical pattern of Glomerulonephritis 
and to observe the changing pattern of Glomerulonephritis in 
our centre during two study periods, i.e. 2000-2006 and 2007-
2008.  
2. To compare our data with the data of other centre. 
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MATERIALS AND METHODS 
 
• The study was done as prospectively from Jan 2007- Dec 2008. 
Retrospective data from Jan 2000-Dec 2006 were retrieved from 
case record. 
• Study centre : Department of Nephrology , Government General 
Hospital , Madras Medical College , Chennai – 600 003  
• Plan of study: All patients who had clinical, laboratory and 
histopathological features of Glomerular disease were analysed. 
• Detailed history and Clinical examination were done to find out 
evidence of volume status, BP measurements and Funduscopic 
examination followed by basic laboratory investigation like 
urine analysis complete blood count, coagulation profile, renal 
function test, liver function test, Chest X–Ray, Ultrasonographic 
examination of the Abdomen with done and basic serelogical 
and immunological workup like HBsAg, anti HCV, HIV, ASO 
Titre and ANA were done. 
• After informed consent Ultrasound guided Renal Biopsy was 
done with spring loaded semi-automatic gun. 
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• All biopsies were evaluated by Light microscopy and 
immunoflorescence.  
• Patients were grouped according to age, gender, presence of 
Hypertension, renal function and their results were analysed.  
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STATISTICAL ANALYSIS 
 
Demographic variables like age, sex and histology categories 
were given in frequencies with their percentages. 
Sex-wise and year wise difference on histological categories was 
analysed using Two Sample Binomial Proportion Test. 
Sex-wise, renal biopsy in diabetes was analyzed using Pearson 
Chi Square Test. 
Decade-wise clinical syndrome was analyzed using Two Sample 
Binomial Proportion Test. 
Comparison with other studies was analysed using Pearson Chi 
Square Test. 
P value less than 0.05 was taken as significant. 
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RESULTS 
 
Distribution of Patients 
• Total number of biopsies done from 2000-2008 is 893 are 
included in this study. 
• Datas were collected from the case records for the years 2000-
2006 and between 2007-2008 were studied prospectively. 
• Total number of biopsies done from 2000-2006 was 454 out of 
which 350(77%) was due to primary glomeluar disease and 
104(23%) was due to secondary gomerular disease. 
• Number of biopsies in 2007-2008 was 439 out of which 342 
(78%) was primary glomeluar disease and 97 (22%) was 
contributed secondary glomeluar disease.  
Table 5.  Distribution of patients 
Histology 2000-06 2007-08 TOTAL 
Primary GN 350 (77%) 342 (78%) 692 
Secondary GN 104 (23%) 97 (22%) 201 
TOTAL 454 439 893 
 
  46
 
The distribution of various primary glomerular diseases are given 
below: 
Table 6. Distribution of Primary Glomerular Disease 
Histology 2000-06 2007-08 Total p value 
MCD 40 (11.4%) 48 (14%) 88 (12.7%) 0.30 
FSGS 69 (19.70) 92 (26.9%) 161(23.2%) 0.03 
IGA 55 (15.7%) 31 (9%) 86 (12.4%) 0.008 
NonIGA mpgn 32 (9.1%) 24 (7%) 56 (8.09%) 0.30 
MGN 48 (13.7%) 35(10.2%) 83(11.9%) 0.16 
MPGN 18(5.1%) 11(3.2%) 29(4.1%) 0.20 
PIGN 42(12%) 59(17.2%) 111(16%) 0.01 
CR.GN 41(11.7%) 37(10.8%) 78(11.2%) 0.10 
TOTAL 350 342 692 - 
 
P=0.05 significant 
Incidence of FSGS and PIGN has increased significantly from 2000-06 
to 2007-08. 
Incidence of IgA nephropathy has decreased significantly from 2000-06 
to 2007-08. 
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Distribution of Primary Glomerular Disease 2000-2006 
MCD 40
FSGS 69
IGA 55
nonIGA 32
MGN 48
MPGN 18
PIGN 42
CR.GN 41
 
 
Distribution of Primary Glomerular Disease 2007-2008 
 MCD 48
FSGS 92
IGA31
nonIGA 24
MGN 35
MPGN 11
PIGN 59
CR.GN 37
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Distribution of Secondary Glomerular Disease  
Number of biopsies done between 2000 and 2006 was 104 
whereas the number of biopsies done between 2007 and 2008 was 
97.The incidence of secondary Glomerular disease –Lupus Nephritis 
was 59(56%), Diabetic nephropathy(Where non diabetic kidney disease 
was suspected) was 31(29%) and Amyloidosis 14(11.4%) respectively 
.In second group between 2007-2008 the number of biopsies done was 
201, Lupus Nephritis was 74(76%), Diabetic nephropathy was 
12(12.3%) and Amyloidosis 11(145%) respectively. 
Table 7. Distribution of Secondary Glomerular Disease 
Histology 2000-06 2007-08 Total P Value 
LN 59(56%) 74(76%) 133(66%) 0.01 
DN 31(29 %) 12(12.3%) 43(21.4%) 0.002 
Amyloidosis 14(13%) 11(11.4%) 25(12.4%) 0.65 
Total 104 97 201  
 
P= 0.05 significant 
Incidence of diabetic nephropathy has decreased in our study because of 
our biopsy protocol. 
This is probably of change in biopsy policy in patients with 
diabetic mellitus with proteinuria. We do biopsy only if patient had 
active urine sediment, micro hematuria, rapidly progressive renal 
failure, absence of retinopathy. 
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Distribution of Secondary Glomerular Disease 2000-2006 
 
LN 59
DN 31
amyloidosis 14
 
 
Distribution of Secondary Glomerular Disease 2007-2008 
LN 74
DN 12
amyloidosis 11
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The Distribution of Age in various Primary Glomerular Disease 
are given below 
Table 8. Distribution of Age in Primary Glomerular Disease 
 
Histology 
No No No M.age M.age M.age
Age 
range 
Age 
range 
Age 
range
00-06 07-08 Total 00-06 07-08 Total 00-06 07-08 Total
MCD 40 48 88 19.3 20.3 19.6 14-40 15-35 14-40
FSGS 69 92 161 27 25.3 26.4 14-65 15-63 14-65
IGA 55 31 86 31.3 35.4 32.8 20-55 18-61 18-61
NonIGA mp 37 29 66 21.1 23.2 22.1 15-62 18-63 15-63
MGN 48 35 83 45.3 40.1 43.2 30-73 33-68 30-73
MPGN 18 11 29 19.2 23.5 21.6 14-30 18-23 14-30
PIGN 42 59 111 23.4 28.1 25.1 16-55 18-61 16-61
CR.GN 41 37 78 28.3 35.5 30.3 20-58 23-61 20-61
 
Mean age is higher in PIGN & Cr.GN .As for FSGS & MGN are 
concerned mean age is lower. 
Table 9. Distribution of Age in Secondary Glomerular Disease 
 
Histology 
No No No M.age M.age M.age
Age 
range 
Age 
range 
Age 
range
00-06 07-08 Total 00-06 07-08 Total 00-06 07-08 Total
LN 59 74 113 24.3 26.3 25 18-62 20-58 18-62
DN 31 12 43 43 39 41.8 33-58 30-49 30-58
Anyloidosis 11 14 25 46 42 45.6 39-63 36-65 36-65
 
The increasing trend observed for mean age in Lupus Nephritis. 
The decreasing trend was observed for Diabetic Nephropathy. 
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The Distribution of Gender in various Primary Glomerluar 
Diseases is given below: 
Table 10. Distribution of Gender in Primary Glomerluar Disease 
Histology 
M/F Ratio 
Total 
00-06 07-08 
MCD 1.4 1.4 1.4 
FSGS 2.2 2.4 2.3 
IGA 2.2 2.5 2.3 
nonIGA mp 1.3 1.6 1.4 
MGN 1.6 1.8 1.7 
MPGN 1.4 1 1.3 
PIGN 2.1 2.6 2.3 
CR.GN 0.8 0.9 0.8 
 
Male predominance was observed in FSGS, IgAN, MGN and PIGN,  
whereas same status was observed for MCD, MPGN and CrGN. 
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The Distribution of Gender in various secondary Glomerluar 
Diseases is given below. 
Table 11. Distribution of Gender in Secondary Glomerular Disease 
Histology 
M/F Ratio 
Total 
00-06 07-08 
LN 0.32 0.20 0.29 
DN 2.3 2.2 2.3 
Anyloidosis 1.3 1.5 1.4 
  
Female predominance was observed in Lupus nephritis whereas male 
dominance was observed in Diabetic nephropathy.  
 
The distribution of various glomerular diseases with age group is 
given below. 
Table 12. Distribution of Glomerular Disease with Age Group 
Histology <30 30-60 >60 Total 
Primary GN 327 308 57 692 
Secondary GN 124 71 6 201 
Total 451 379 63 893 
 
Incidence of primary glomerular disease was similar between 30 
to 60 years and less than 30 years, whereas incidence of secondary 
glomerular disease was higher in less than 30 years of age group. 
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The Distribution of various Primary Glomerular Diseases with 
Age group is given below. 
Table 13. Distribution of Primary Glomerular Disease with Age 
Group 
Histology <30 30-60 >60 Total P Value
MCD 66(21.2%) 22(7.1%) 0 88 0.001 
FSGS 84(25.6%) 70(22.7%) 7(17.3%) 161 0.01 
IGA 20(7.9%) 53(17.2%) 13(22.8%) 86 0.001 
NonIgA mp gn 34(10.4%) 18(5.8%) 4(7%) 56 0.101 
MGN 7(2.1%) 60(19.4%) 16(20%) 83 0.01 
MPGN 22(6.7%) 7(2.2%) 0 29 0.01 
PIGN 75(22.9%) 27(8.7%) 9(15.8%) 111 0.101 
CR.GN 19(5.8%) 51(16.5%) 8(14%) 78 0.001 
 
P=0.05 significant 
Incidence of MCD, PIGN and FSGS was higher < 30 years of age 
group. Incidence of IgA, CrGN & MGN nephropathy was more in the 
age group between 30 to 60 years. 
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The Distribution of various Secondary glomerular diseases with 
Age Group is given below. 
Table 14. Distribution of Secondary glomerular disease with Age 
Group 
Histology <30 30-60 >60 Total P Value
LN 117(94.3%) 14(19.7%) 2(33.3%) 133 0.10 
DN 4(3.2%) 38(53.5%) 1(16.6%) 43 0.10 
Amyloidosis 3(2.4%) 19(26.7%) 3(50%) 25 0.001 
Total 124 71 6 201  
 
P=0.05 
Incidence of lupus nephritis was higher in less than 30 years of 
age group. Incidence of diabetic nephropathy was seen in 30 to 60 years. 
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The Clinical Presentation of various Glomerular Diseases at 
initial presentations is given below.  
Table 15. Clinical Presentation of Glomerular Disease on 
Presentation 
Histology Edema Oliguria
Macrohe-
maturia 
Fever Anorexia Dyspnoea Total 
MCD 80 6 0 12 6 6 88 
FSGS 98 26 3 18 23 31 161 
IGA 21 23 25 8 21 19 86 
nonIGA mp 15 13 2 7 3 7 56 
MGN 40 7 3 3 7 8 83 
MPGN 12 2 3 7 4 3 29 
PIGN 60 71 24 25 19 23 111 
CR.GN 60 55 21 23 33 35 78 
LN 31 23 17 43 23 20 133 
DN 36 21 1 7 8 10 43 
Amyloidosis 12 4 0 3 3 3 25 
 
MCD (90.9%), FSGS (60.8%) & MGN (48.1%) are most commonly 
presented with edema. 
In IgA nephropathy, 29% had Macrohaematuria. 
In PIGN 63.96 % had Oliguria 18% had Marohaematuria. 
In CrGN 76.92% had edema, 70.5% had oliguria 26.92% had 
macrohaematuria. 
In Lupus nephritis 32.3% had fever 17.29 had oliguria. 
In diabetic nephropathy, 83.72% had edema. 
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The Examination Findings of various Glomerular Diseases at 
initial presentations are given below.  
Table 16. Examination Findings of Glomerular Disease on 
Presentation 
Histology Edema Ht Retinopathy 
Pleural 
effusion 
Ascitis Total
MCD 84 10 0 32 33 88 
FSGS 106 41 31 31 32 161 
IGA 25 34 12 9 8 86 
nonIGA mp 18 16 3 2 3 56 
MGN 45 27 13 5 4 83 
MPGN 15 12 5 3 2 29 
PIGN 73 65 4 12 11 111 
CR.GN 66 53 8 19 7 78 
LN 36 70 23 33 21 133 
 
Incidence of hypertension in MCD (11.36%), FSGS (25.46%), MGN 
(32.53%). 
Incidence of hypertension in IgA nephropathy (39.53%), PIGN 
(28.55%). 
Incidence of hypertension in CrGN (67.94%). 
Incidence of hypertension in lupus nephritis (52.63%) 
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The lab features of various primary and secondary diseases are 
given below: 
Table 17. Lab Features of Glomerular Disease 
Histology 
Microhe-
maturia 
Blood 
urea 
>7 
Mmol
Sr.creat 
>130 
micromo
Chol 
>200 
mg/dl
Avg.
Urine 
pcr 
Avg.sr. 
Albumin 
<3g/dl 
Total
MCD 12 3 2 52 6.2 43 88 
FSGS 36 53 48 73 2.8 73 161 
IGA 41 34 31 10 2.1 2.2 86 
nonIGA mp 11 13 11 8 1.3 7 56 
MGN 37 13 10 12 5.8 22 83 
MPGN 8 7 6 7 3.1 8 29 
PIGN 73 73 69 9 3.1 9 111 
CR.GN 69 61 63 5 3.3 13 78 
LN 101 33 30 8 2.1 12 133 
DN 13 29 20 21 4.3 16 43 
Amyloidosis 2 6 4 7 3.6 10 25 
 
In MCD 2 of them presented with renal failure. One had sepsis 
(22 yrs) due to spontaneous bacterial peritonitis and recovered with 
antibiotics. Another person (41 yrs) presented with renal vein 
thrombosis recovered with anticoagulant and 52 of them had cholesterol 
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more than 200 mg/dl with average urine PCR 6.2 and 43 of them 
presented with hypo Albuminemia. 
In FSGS 48 of them presented with renal failure and 73 of them 
presented with hyper lipidemia. 
In IgA nephropathy 41 of them presented with micro hematuria 
and 31 of them presented with renal failure.  
In PIGN 69 of them presented with renal failure. 
In CrGN 69 of them presented with micro hematuria and 63 of 
them presented with renal failure. 
In lupus nephritis 30 of them presented with renal failure and 8 of 
them had hyper lipidemia. 
In diabetic nephropathy 20 of them presented with renal failure. 
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Table 18. Comparison with Other Studies 
Histological 
Categories 
MMC 
Study 
(n=893) 
CMC, 
Vellore
(n=4035)
Minnesota
(n=195) 
Italian 
Study 
(n=13835)
Pearson 
Chi 
Square 
Test 
Comparison 
between 
Studies 
n % n % n % n %   
FSGS 161 11.79 677 16.8 33 21.5 1730 12.5
χ2 
=181.6 
P=0.001 
1 Vs 2,3 
PIGN 111 7.70 543 13.5 7 3.6 360 2.6 
χ2 
=760.1 
P=0.001 
1 Vs 2,3,4 
MCD 88 6.48 433 10.8 8 4.1 1065 7.7 
χ2 
=162.2 
P=0.001 
1 Vs 2 
Mesangial 
PGN 
56 5.09 293 7.3   1231 8.9 
χ2 
=36.75 
P=0.001 
1 Vs 2,4 
MN 83 5.92 384 9.5 20 10.2 3127 22.6.
χ2 =572 
P=0.001 
1 Vs 2,3,4 
IgAN 86 6.04 338 8.4 42 21.5 5188 37.5
χ2 
=173.1 
P=0.001 
1 Vs 2,3,4 
Lupus 
Nephritis 
133 8.97 279 6.9 25 12.8   
χ2 
=14.71 
P=0.001 
1 Vs 2 
Crescentic 
GN 
78 4.21 140 3.5 10 5.1 941 6.8 
χ2 
=72.64 
P=0.001 
1 Vs 2,4 
Diabetic 
Nephropathy 
43 3.77 111 2.8     
χ2 =4.32 
P=0.04 
1 Vs 2 
Amyloidosis 75 4.15 41 1.0 5 2.6   
χ2 =62.8 
P=0.001 
1 Vs 2 
 
  60
The results of this study correlate significantly with south Indian 
study (CMC, Vellore) for FSGS, MCD, MN, IgAN and Lupus 
Nephritis. 
The results of this study significantly correlate with Italian study 
and US study for the following IgAN, MGN and PIGN. 
  61
 
DISTRIBUTION OF PRIMARY GLOMERULAR DISEASE
40
69
55
32
48
18
42 41
48
92
31
24
35
11
59
37
0
10
20
30
40
50
60
70
80
90
100
MCD FSGS IGA nonIGA mp MGN MPGN PIGN CR.GN
N
o.
 o
f p
at
ie
nt
s
2000-06
2007-08
 
 
1.4
2.3 2.3
1.4
1.7
1.3
2.3
0.8
0.21
2.3
1.4
0
0.5
1
1.5
2
2.5
M
/F
 r
at
io
MCD FSGS IGA nonIGA
mp
MGN MPGN PIGN CR.GN LN DN Anyloid
DISTRIBUTION OF GENDER RATIO AMONG 
GLOMERULAR DISEASE
 
 
  62
 
19.6
26.4
32.8
22.1
43.2
21.6
25.1
30.3
25
41.8
45.6
0
5
10
15
20
25
30
35
40
45
50
%
 o
f p
at
ie
nt
s
MCD FSGS IGA nonIGA mp MGN MPGN PIGN CR.GN LN DN Amyloid
DISTRIBUTION OF MEAN AGE  OF GLOMERULAR DISEASE
 
 
DISTRIBUTION OF AGEWISE PRIMARY GLOMERULAR DISEASE
0
10
20
30
40
50
60
70
80
90
100
MCD FSGS IGA nonIGA
mp
MGN MPGN PIGN CR.GN LN DN Amyloid
N
o.
 o
f p
at
ie
nt
s
<30
30-60
>60
 
  63
 
DISTRIBUTION OF GLOMERULAR DISEASE
0
20
40
60
80
100
120
MCD FSGS IGA nonIGA mp MGN MPGN PIGN CR.GN LN DN Amyloid
N
o.
 o
f p
at
ie
nt
s
micro
bu
scr>130
chol>200
sr.alb<3
 
 
CLINICAL PRESENTATION OF GLOMERULAR PRESENTATION OF 
GLOMERULAR DISEASE AT PRESENTATION
0
20
40
60
80
100
120
MCD FSGS IGA nonIGA
mp
MGN MPGN PIGN CR.GN LN DN Amyloid
N
o.
 o
f p
at
ie
nt
s
Edema
dis
nep
fever
ano
dys
 
 
  64
 
 
 
 
EXAMINATION FINDINGS OF GLOMERULAR DISEASE AT PRESENTATION
0
20
40
60
80
100
120
MCD FSGS IGA nonIGA mp MGN MPGN PIGN CR.GN LN DN Amyloid
N
o.
 o
f p
at
ie
nt
s
Edema
HT
Ratiopathy
pl.effusion
Asctis
 
  65
 
DISCUSSION 
 
It has been widely accepted that MCNS is by far the most 
common cause of nephrotic syndrome in children in ISKDC. It was 
reported almost 30 years ago that MCD was present in 77% all renal 
biopsies performed in children with idiopathic nephrotic syndrome [6]. 
In our study 12.7% of them presented with MCD and two of them 
had renal failure and recovered. In this study, the relative decline in the 
frequency of minimal change nephropathy could be that fewer patients 
with such regions are actually being subjected to biopsy [25]. Studies 
from Siegel et al. and Trachtman et al. have shown a higher incidence of 
FSGS in pediatric patients with steroid sensitive nephrotic syndrome, 
but increased incidence of FSGS is reported in steroid dependent and 
frequent relapsers. According to D’Agati and has increased incidence of 
FSGS has been observed in recent years [26]. 
In this study results demonstrate a high incidence of FSGS which 
contributes to 23.2%. Ethnicity seems to play a critical role in the 
epidemiology of nephrotic syndrome [27] and observed, strong 
predominance of FSGS among African Americans. A potential 
explanation for this recent surge in FSGS could be a change in ethnic 
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composition of our population [28]. Another consideration for the risk 
in the incidence of FSGS is a potential increase in the age of patients 
who are resistance to corticosteroid (R).Unfortunately, because the 
etiology of FSGS in unknown, it is difficult to postulate a potential 
mechanism for this increasing incidence [29]. 
We cautiously excluded from this study patients with identified 
systemic disease are conditions known to be associated with FSGS like 
HIV, heroin abuse and drugs like lithium and palmidronate etc.  
However, it is recognized that a wide variety of factors can trigger 
a response in nephron that would eventually lead to the development of 
the histological lesions of FSGS. FSGS also appears to be a rather 
heterogeneous condition. For example, circulating factors cause 
proteinuria in FSGS patients, particularly those who have recurrence of 
the disease following renal transplant. 
We also observe a lower relative frequency of MPGN (inclusive 
of all subtypes) and also relatively higher frequency of IgAN (R).In this 
study as well as that of Korbete et al. suggested that IgAN should be 
considered in the differential diagnosis of adult nephortic syndrome of 
unknown etiology, particularly in young patients [30]. 
Korbete et al. (R) noted a decrease in the incidence of MGN in 
black individuals, compared with an increase of approximately 10% 
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over 10 years in the white individuals (R).In this study findings suggest 
increase in incidence of MGN significantly higher (11.9). 
In this Study the incidence of lupus nephritis has increased 
significantly with Class 4 & Class 5 types. Increasing incidence of male 
lupus has also observed in this study. 
The incidence of Diabetic Nephropathy was more common in age 
group of 30yrs and above as expected .In this study only limited number 
of Diabetic patients were subjected to Renal Biopsy if they had any 
indication like active urine sediment, significant proteinuria without 
Diabetic retinopathy, unusual or rapid decline in renal function, massive 
proteinuria unexplained renal failure with normal size kidney [31]. 
Total number of Biopsies done in this study was 43 out of which 
23 were due to Diabetic Nephropathy and 13 were due to non diabetic 
renal disease and 10 of them due to had both Diabetic Nephropathy and 
non diabetic disease. 
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Table 19. Renal Biopsy in Diabetics 
Sex 
ND NDRD DN+NDRD 
Tota
l 
No. of 
Patient
s 
Percentag
e (%) 
No. of 
Patient
s 
Percentag
e (%) 
No. of 
Patient
s 
 
Percentag
e (%) 
 
 
Male 
 
 
16 
 
 
37.29 
 
 
8 
 
 
18.06 
 
 
7 
 
 
16.27 
 
 
31 
 
Femal
e 
 
7 
 
16.27 
 
2 
 
24.65 
 
3 
 
6.92 
 
12 
Total 23  10  10  43 
 
Table 20. Non-Diabetic Renal Disease 
Type of Renal lesion 
Male 
(n=31) 
Female 
(n=12) 
Percentage, 
% (n=43) 
Membranous Nephropathy  5 2 16.27 
Post Infectious 
Glomerulonephritis  
6 2 18.06 
Acute Interstitial Nephritis  2 1 6.97 
Acute Tubular Necrosis  2 - 4.65 
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For non-diabetic Renal disease membranous nephropathy 
contributes to 16.27%. Highest incidence of non-diabetic renal disease 
was PIGN which is about 18.06 %. AIN contributes 6.97% whereas 
ATN contributes only 4.65 %. 
Finally we also found that in significant fractions of patients, at 
least more than 55years of age with unexplained nephrotic syndrome, 
had amyloid nephropathy although amyloid is not a primary renal 
disease. But we included in this study of patients with unexplained 
nephrotic syndrome if at the time of biopsy they had no known evidence 
of a systemic disease related to amyloid [32]. 
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TRIALS DONE FOR CHANGING TREND OF 
GLOMERULAR DISEASE 
 
Changing incidence of glomerular disease Olmsted County, 
Minnestoa: a 30 year renal biopsy study 
Sundararaman swaminathan et al Clinical J Am Soc Nephrol 1: 
483-487, 2006 [21].  
Period of study: 1974-2003 Retrospective time trends in the 
annual age: and gender adjusted (2000 US population) incidence rate per 
1,00,000 on Olmsted county residents estimated. 
Total numbers of 195 biopsies were analysed. 
IgN nephropathy -22 %, FSGS-17%, MGN-10%. 
Between 1974-1983 and 1994-2003 incidence of any type of GN 
among Olmsted county residents increased more than 2-fold (P<0.001). 
FSGS-13-fold(P<0.001), IgAN – 3 fold(P=0.002), MGN-2.5 fold 
(P=0.13). 
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1994 to 2003 IgAN 25% annual incidence rate 2.1 per 100000/ 
year, FSGS 20% annual incidence rate 1.8/100000 per year, MGN 11% 
annual incidence rate 1.0/100000 per year. 
This study confirms that the incidence of GN is growing overall 
particularly FSGS which is the leading cause of nephrotic syndrome in 
white adults. 
Spectrum of biopsy proven renal disease and changing trends at a 
tropical tertiary care center 1990-2001 
N Balakrishnan, George T John et al. Indian J Nephrol 2003; 
13:29-35 [22].  
Period of study: 1994-2001 
Total number of biopsy -4035 
MCD-47.2% 
FSGS-12.5% 
PIGN-8.8% 
Non IgA Misangial PGN-11.3% 
Lupus nephritis -3.5% 
MPGN-2.6% 
Non diabetic renal disease-72% 
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Between 1970 and 1985, MCD-8.7%, FSGS – 22%, MGN-11%, 
MPGN-7.2%, PIGN-40.7%. 
In this study MCD, FSGS, Misangial PGN and PIGN were 
significantly more common in the present study. 
SURVEY OF THE ITALIAN REGISTRY OF RENAL BIOPSIES 
Frequency of renal disease for 7 consecutive years 
F.P.Schena et al Nephrol dial Transplant (1997)12:418-426 [23]. 
Period of study: 1987-1993 
Total number of biopsies: 15461 
Between 1987-1989 Primary glomerular disease -59.9% 
IgAN - 36.9% 
MGN-21.7% 
FSGS-10.4% 
Secondary glomerular disease – 25.4% 
Lupus nephritis-51.6% 
Amyloidosis-39.3% 
In 1993 MGN-32.9%, FSGS-12.3%, MCD-12%, 
PIGN-16.1%, IgAN-14%. 
Primary glomerular disease (22.7 p.m.p) 
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Secondary glomerular disease (11.8 p.m.p ) 
The frequency of main groups of nephrotic syndrome and the 
distribution of different GN changes only slightly over a long period. 
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CONCLUSIONS 
 
Our studies show that the most common primary glomerular 
disease is FSGS, followed by PIGN, IGAN, MCNS and MGN, in that 
order, respectively. 
There is increased incidence of FSGS and PIGN during the year 
2007-08.  
The mean age of presentation for FSGS and MGN was lower 
during 2007-08.  
The occurrence of FSGS, PIGN and MCN was seen more in 
younger age group, while in elderly patients, IgA nephropathy was 
common primary glomerular disease. 
Our studies have shown decreased incidence of MCD, FSGS, IgA 
nephropathy and MGN, and increased incidence of lupus nephritis 
compared to CMC studies. 
The incidence of Crescentic GN and diabetic nephropathy was 
similar in both the studies. 
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WORK SHEET 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 Total
FSGS 13 10 14 4 20 8 32 28 32 161 
PIGN 5 7 6 9 8 7 20 20 19 111 
MCD 7 11 8 2 10 9 17 19 4 88 
Mesangial 
PGN 
5 8 5 2 5 6 9 14 6 56 
MN 9 4 13 10 4 8 10 12 13 83 
IgAN 6 10 9 12 9 9 15 9 7 86 
Lupus 
Nephritis 
13 5 8 18 8 17 24 28 22 133 
Crescentic 
GN 
7 10 9 9 8 8 6 8 14 78 
Diabetic 
nephropathy 
5 0 4 5 4 13 5 3 4 43 
MPGN 2 8 2 5 7 1 4 3 4 29 
Amyloidosis 1 1 0 5 2 5 3 4 4 25 
 
 
